Brian Savage Sells 7,342 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Brian Savage sold 7,342 shares of the company’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the transaction, the insider owned 8,500 shares of the company’s stock, valued at approximately $330,225. The trade was a 46.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA traded down $0.50 on Tuesday, hitting $39.56. The stock had a trading volume of 4,542,487 shares, compared to its average volume of 6,865,542. The company’s 50-day moving average is $35.58 and its two-hundred day moving average is $33.60. Teva Pharmaceutical Industries Ltd. has a one year low of $18.21 and a one year high of $40.79. The stock has a market cap of $46.10 billion, a price-to-earnings ratio of 65.93, a P/E/G ratio of 4.86 and a beta of 0.87. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. On average, analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of recent analyst reports. Leerink Partners started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price objective for the company. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Barclays increased their target price on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Weiss Ratings cut Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, September 8th. Finally, Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $43.10.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently modified their holdings of TEVA. Bullseye Investment Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth $68,000. Sequoia Financial Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 12.5% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 190,940 shares of the company’s stock valued at $6,469,000 after purchasing an additional 21,240 shares during the last quarter. National Pension Service lifted its stake in shares of Teva Pharmaceutical Industries by 4.9% in the 2nd quarter. National Pension Service now owns 2,406,013 shares of the company’s stock valued at $81,516,000 after purchasing an additional 112,357 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD bought a new stake in Teva Pharmaceutical Industries in the second quarter worth $33,799,000. Finally, IFP Advisors Inc boosted its holdings in Teva Pharmaceutical Industries by 1.1% in the second quarter. IFP Advisors Inc now owns 143,876 shares of the company’s stock worth $4,875,000 after purchasing an additional 1,532 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.